Galapagos NV (GLPG) News
Filter GLPG News Items
GLPG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
GLPG News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest GLPG News From Around the Web
Below are the latest news stories about GALAPAGOS NV that investors may wish to consider to help them evaluate GLPG as an investment opportunity.
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%Galapagos (GLPG) said Wednesday that it plans to split into two entities, with a new company, or Spi |
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded EntitiesGalapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncolog |
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceMechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 pm PT in San Francisco.A live webcast of the presentation will be accessible on the Investors page of the Company’s website at www.glpg.com/investors. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days.In ad |
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25%Key Insights Galapagos' significant retail investors ownership suggests that the key decisions are influenced by... |
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapyThis early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL. |
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaData from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96% of patients received an infusion of fresh, fit, stem-like, early memory CD19 CAR T-cell therapy with a median vein-to-vein time of seven days, avoiding the need for cryopreservation and bridging therapy.These data reinforce the potential of Galapagos’ decentralized cell therapy manufacturing platf |
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our c |
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023)Galapagos ( AMS:GLPG ) Third Quarter 2024 Results Key Financial Results Revenue: €59.8m (down 50% from 3Q 2023). Net... |
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ...Galapagos NV (GLPG) reports a robust cash reserve and significant advancements in its R&D pipeline, while navigating increased R&D costs and competitive market pressures. |
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business UpdateWe are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance o |